HaoNguyenMDPhD
Urology • San Francisco, CAMinimally Invasive Surgery, Surgical Oncology
Associate Professor, UCSF School of Medicine Richard and Lelani Grinold endowed professor
Dr. Nguyen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 4th Street, 4th Floor
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 94158Phone+1 415-353-7100
Education & Training
University of California (San Francisco)Fellowship, Minimally Invasive Urologic Surgery, 2013 - 2015
University of California Davis HealthResidency, Urology, 2009 - 2013- University of California Davis HealthResidency, Surgery, 2007 - 2009
Boston University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2008 - 2026- American Board of Urology Urology
Clinical Trials
- Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer Start of enrollment: 2015 Dec 22
Publications & Presentations
PubMed
- Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.Mary O Fakunle, Janet E Cowan, Samuel L Washington 3rd, Katsuto Shinohara, Hao G Nguyen
The Journal of Urology. 2025-01-01 - 4 citationsThe state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement.Juan Javier-DesLoges, Marc A Dall'Era, Wayne Brisbane, Karim Chamie, Samuel L Washington 3rd
Prostate Cancer and Prostatic Diseases. 2024-12-01 - Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance.Kevin Shee, James Nie, Janet E Cowan, Lufan Wang, Samuel L Washington 3rd
European Urology Oncology. 2024-09-27
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Press Mentions
Drug ISRIB Is a Memory Enhancer, Anti Cancer Agent, Protects Hearing and Perhaps Has Anti Aging EffectsDecember 27th, 2020
Research Finds ‘Achilles Heel’ for Aggressive Prostate CancerMay 14th, 2018
Experimental Treatment Is 'Achilles Heel' for Aggressive Prostate TumorsMay 3rd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
